Alan B Lancz & Associates Inc. Sells 100 Shares of Becton, Dickinson and Company $BDX

Alan B Lancz & Associates Inc. reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 5.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,660 shares of the medical instruments supplier’s stock after selling 100 shares during the period. Alan B Lancz & Associates Inc.’s holdings in Becton, Dickinson and Company were worth $286,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Northcape Wealth Management LLC raised its position in Becton, Dickinson and Company by 0.5% in the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after buying an additional 51 shares during the last quarter. Diversified Trust Co raised its position in Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after buying an additional 53 shares during the last quarter. Bill Few Associates Inc. raised its position in Becton, Dickinson and Company by 0.7% in the 2nd quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after buying an additional 55 shares during the last quarter. Horizon Bancorp Inc. IN raised its position in Becton, Dickinson and Company by 10.9% in the 1st quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 56 shares during the last quarter. Finally, Meadow Creek Wealth Advisors LLC raised its position in Becton, Dickinson and Company by 5.4% in the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 1,161 shares of the medical instruments supplier’s stock valued at $266,000 after buying an additional 59 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 1,838 shares of company stock valued at $348,392. Company insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Morgan Stanley increased their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Argus increased their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday. Finally, Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Trading Up 2.1%

Shares of Becton, Dickinson and Company stock opened at $189.20 on Monday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a market cap of $54.23 billion, a PE ratio of 34.03, a P/E/G ratio of 1.48 and a beta of 0.25. The stock has a fifty day moving average price of $190.60 and a 200-day moving average price of $184.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.32 billion during the quarter. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a $1.04 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.